Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis

被引：3

作者：

Nagi, W. ^{[1
]}

Lim, Z. Y. ^{[1
]}

Krishnamurthy, P. ^{[1
]}

Potter, V. ^{[1
]}

Tindell, V. ^{[1
]}

Reiff-Zall, L. ^{[1
]}

Abdullah, A. ^{[1
]}

Lea, N. ^{[1
]}

Kenyon, M. ^{[1
]}

Marsh, J. ^{[1
]}

Ho, A. Y. L. ^{[1
]}

Mufti, G. J. ^{[1
]}

Pagliuca, A. ^{[1
]}

机构：

[1] Kings Coll London, Dept Haematol Med, Kings Coll Hosp NHS Fdn Trust, London WC2R 2LS, England

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 08期

基金：

英国医学研究理事会;

关键词：

Myelofibrosis; Allogeneic; Alemtuzumab; SCORING SYSTEM; MUTATION;

D O I：

10.1016/j.leukres.2011.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：998 / 1000

页数：3

共 50 条

[1] NONMYELOABLATIVE AND REDUCED INTENSITY CONDITIONING IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS
Malone, A. K.
Scigliano, E.
Grosskreutz, C.
Osman, K.
Isola, L.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S285 - S285
[2] Allogeneic reduced intensity conditioning regimen haematopoietic stem cell transplantation
Fürst, S
Dubois, V
Michallet, AS
Nicolini, F
Thomas, X
Troncy, J
Rafii, H
Gebuhrer, L
Michallet, M
[J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S329 - S329
[3] Allogeneic haematopoietic stem cell transplantation with reduced intensity conditioning regimens ("minitransplants")
Schanz, U
[J]. SWISS MEDICAL WEEKLY, 2001, 131 (5-6) : 59 - 64
[4] Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
Alchalby, Haefaa
Kroeger, Nicolaus
[J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2010, 5 (02) : 53 - 61
[5] Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
Haefaa Alchalby
Nicolaus Kröger
[J]. Current Hematologic Malignancy Reports, 2010, 5 : 53 - 61
[6] Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
Kim, Dong Hyun
Seo, Jeongmin
Shin, Dong-Yeop
Koh, Youngil
Hong, Junshik
Kim, Inho
Yoon, Sung-Soo
Byun, Ja Min
[J]. BLOOD RESEARCH, 2022, 57 (04) : 264 - 271
[7] Long term outcomes of adults undergoing alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation
Ceesay, M. Mansour
Lim, ZiYi
Kenyon, Michelle
Ho, Aloysius Y. L.
Devereux, Stephen
Schey, Steve
Mijovic, Aleksandar
Pagliuca, Antonio
Mufti, Ghulam J.
[J]. BLOOD, 2007, 110 (11) : 496A - 497A
[8] A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab
Ho, Aloysius Y. L.
Krishnamurthy, Pramila
Lim, ZiYi
Kenyon, Michelle
Mijovic, Aleksander
Devereux, Stephen
Pagliuca, Antonio
Mufti, Ghulam J.
[J]. BLOOD, 2009, 114 (22) : 893 - 893
[9] Reduced intensity allogeneic stem cell transplantation in patients with myelofibrosis
Bloor, AJC
Ahmed, O
Dimpoulou, M
Fielding, AK
Chakraverty, R
Parker, AN
Liakopoulou, E
Goldstone, AH
Thomson, K
Mackinnon, S
Kottaridis, P
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 13 - 13
[10] Long term outcomes of adults undergoing alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation
Ceesa, M. M.
Lim, Z. Y.
Kenyon, M.
Ho, A.
Devereux, S.
Schey, S.
Mijovic, A.
Pagliuca, A.
Mufti, G. J.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 53 - 54

← 1 2 3 4 5 →